ABOUT PRODUCTS PIPELINE IMPACT INVESTORS CAREERS CONTACT US INTELLIGENTLY MINING THE MARKET INVESTORS + NEWS We’re creating unmatched value through enhanced treatments and valued partnerships. And with an estimated $3.4 billion in annual brand sales, we believe we’re just getting started on our mission to maximize the full potential of treatments for patients and physicians around the globe. SEE OUR BUSINESS STRATEGY IN ACTION EAGLE PHARMACEUTICALS 2020 ANNUAL REPORT Featured Press Release Eagle Pharmaceuticals to Present at Piper Sandler 33rd Annual Healthcare Conference 2021 11/22/21 06:50 am WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present virtually at the Piper Sandler 33rd Annual Healthcare Conference 2021 as follows: See More Eagle Pharmaceuticals Reports Third Quarter 2021 Results 11/9/21 06:50 am Q3 2021 net loss was $0.43 per basic and diluted share and adjusted non-GAAP net income was $0.57 per basic and $0.56 per diluted share Expect to receive approval for Abbreviated New Drug Application (“ANDA”) for vasopressin; December 15, 2021 GDUFA date Received favorable district court decision that Eagle’s proposed vasopressin product does not infringe any of the patents Par asserted against Eagle Entered into worldwide licensing agreement for CAL0... SEE MORE Eagle Pharmaceuticals to Host Third Quarter 2021 Financial Results on November 9, 2021 10/28/21 05:05 pm WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)-- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2021 third quarter financial results on Tuesday, November 9, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: See More Upcoming Events & Presentations No items found. Featured Presentation CAL02 Investor Day NASDAQ: EGRX 48.10 Change % -2.12 Volume62,521 Data as of 11/26/2021 1:00 PM Minimum 20 minute delay. Investor Center Home Press Releases Corporate Governance Stock Information SEC Filings Events & Presentations Analyst Coverage Investor FAQs Email Alerts RSS Feeds Investor Contact In-Site Communications, Inc. Lisa M. Wilson, 212-452-2793 For all other media inquiries, please contact us. REQUEST A MEETING WITH MANAGEMENT PRIVACY POLICY TERMS OF USE SITEMAP CONTACT US © 2021 Eagle Pharmaceuticals, Inc. All rights reserved. Woodcliff Lake, NJ 07677 Powered By Q4 Inc. 5.56.0.1 (opens in new window)